Skip to the page

Data / Form D filings / Everest Biolabs, Inc.

Everest Biolabs, Inc.: Form D filing

Everest Biolabs, Inc., a biotechnology company in Waltham, MA, filed a Form D with the SEC in 2026. The latest, on March 11, 2026, reports $4.4 million sold of a $5.7 million offering to 7 investors.

SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.

Company details from the filing

Address
204 SECOND AVE SUITE 102, Waltham, MA, 02451
Phone
(617) 214-0840
Industry
Biotechnology
Entity type
Corporation
Incorporated in
Delaware
Year incorporated
2024
Revenue range
Decline to Disclose
Exemptions claimed
Rule 506(b)
SEC identifier (CIK)
2116676

Form D filings

FiledTypeOfferingSoldRemainingInvestorsFirst saleFiling
Mar 11, 2026New notice$5,650,000$4,350,000$1,300,0007Feb 25, 2026sec.gov

Executive officers and directors named in the filing

NameRoleNote in the filing
George DaaboulExecutive Officer, Director
David FreedmanExecutive Officer, Director
David WaltDirector
Paul MeisterDirector
Vinit NijhawanDirector

Other biotechnology companies in Massachusetts that filed recently

Every Form D from the week of Mar 9, 2026 · All recent filings in Massachusetts · All recent Biotechnology filings

Read from SEC EDGAR. Amount sold is what Everest Biolabs, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.